From Handshake to Breakthrough: How Generative AI Helped Design a Brain-Penetrant Cancer Drug Candidate (Webinar Recording)
In this 60-minute fireside chat, Rakovina Therapeutics and Variational AI share the story behind an AI-designed, CNS-penetrant dual ATR/mTOR inhibitor program—and what it could mean for future cancer therapies.
Leaders from both teams discuss how a shared frustration with slow, trial-and-error drug discovery sparked the partnership, and how Variational AI’s Enki™ generative AI platform helped design brain-penetrant ATR/mTOR candidates around Rakovina’s biological “wish list.” The conversation also covers what the SNO 2025 preclinical data suggest about potency, selectivity, and CNS exposure, and where the program goes next—plus how this repeatable approach can be applied to future assets.